List of Excipients in Branded Drug NITROGLYCERIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rouses Point Pharm	NITROGLYCERIN	nitroglycerin	43478-410	BUTANE
Rouses Point Pharm	NITROGLYCERIN	nitroglycerin	43478-410	CAPRYLIC/CAPRIC/SUCCINIC TRIGLYCERIDE
Rouses Point Pharm	NITROGLYCERIN	nitroglycerin	43478-410	MENTHOL

Generic Drugs Containing NITROGLYCERIN

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc.	nitroglycerin	0378-9102	TITANIUM DIOXIDE
American Regent, Inc.	nitroglycerin	0517-4810	ALCOHOL
American Regent, Inc.	nitroglycerin	0517-4810	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in NITROGLYCERIN?

# Of NDCs	Excipient
3	ALCOHOL
44	CALCIUM STEARATE
1	CELLULOSE, MICROCRYSTALLINE

Excipient Strategy and Commercial Opportunities for Nitroglycerin

Last updated: March 1, 2026

What are the key excipient strategies for nitroglycerin formulations?

Nitroglycerin is a potent vasodilator used mainly in acute angina management. Its pharmacokinetic profile is sensitive to formulation excipients, which influence stability, bioavailability, and patient compliance.

Formulation considerations

• Stability: Nitroglycerin is sensitive to heat, light, and moisture. Excipient choices focus on protecting against degradation.
• Delivery system: Sublingual tablets, sprays, patches, and ointments each require specific excipient profiles.
• Bioavailability enhancement: Use of permeation enhancers (e.g., cyclodextrins) or solubilizers (e.g., ethanol) to improve absorption.

Typical excipients used

• Sweeteners: Mannitol, sorbitol, to mask bitter taste and improve patient compliance.
• Humectants: Glycerin, to prevent moisture loss.
• Permeation enhancers: Cyclodextrins, to increase membrane permeability.
• Stabilizers: Ascorbic acid to prevent oxidation.
• Base materials: Lactose, microcrystalline cellulose, for tablet formation.
• Adhesives and binders: Polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC).
• Phases in patches: Polymeric matrices such as polyisobutylene or polyacrylates.

Formulation challenges

• Mitigating nitroglycerin's sensitivity by selecting excipients that suppress decomposition.
• Ensuring rapid disintegration for sublingual forms without sacrificing stability.
• Achieving controlled release in transdermal patches.

What commercial opportunities exist based on excipient innovations?

Expanding dosage forms

• Sublingual tablets: Development of faster-dissolving formulations with superdisintegrants like sodium starch glycolate.
• Transdermal patches: Incorporation of biocompatible polymers to prolong release and enhance stability.
• Ointments and gels: Use of permeation enhancers for topical delivery targeting chronic angina.

Enhancing product stability and shelf-life

• Incorporation of antioxidants and moisture barriers to extend expiration.
• Use of novel packaging solutions, such as blister packs with moisture barriers.

Novel excipients in development

• Cyclodextrin inclusion complexes: Improved solubility and stability.
• Nanoparticle carriers: Encapsulating nitroglycerin in liposomes or polymeric nanoparticles to control release and minimize degradation.

Regulatory landscape and potential market size

• Favorable regulatory pathways for innovative excipient use, especially for generic formulations.
• The global angina drug market expected to reach USD 8.6 billion by 2028 (MarketsandMarkets, 2022).
• Patent opportunities exist for formulations utilizing proprietary excipients or novel delivery systems.

Competitive landscape

• Major pharmaceutical firms focus on innovative delivery systems for nitroglycerin.
• Generic manufacturers leverage excipient optimizations to reduce costs and improve stability.

How can companies leverage excipient strategies for commercial advantage?

1. Innovation: Develop formulations that improve bioavailability or extend shelf life.
2. Patient compliance: Create palatable, fast-melting sublingual tablets or convenient patches.
3. Regulatory positioning: Use excipient innovations to obtain patents, securing market exclusivity.
4. Cost efficiency: Optimize excipient use to reduce manufacturing costs without compromising quality.

Key Takeaways

• Excipient choices directly impact nitroglycerin stability, bioavailability, and patient adherence.
• Innovation in excipient technology presents opportunities for new dosage forms and enhanced products.
• Market growth driven by angina prevalence supports investments in formulation enhancements.
• Patent protection and regulatory strategies are critical for maximizing commercial gains.
• The competitive landscape favors firms that combine excipient innovation with delivery system advancements.

FAQs

1. What are the main challenges in formulating nitroglycerin?
Nitroglycerin’s sensitivity to heat, light, and moisture complicates formulation. Achieving stability without sacrificing rapid action is crucial.

2. Which excipients are most common in nitroglycerin patches?
Polyisobutylene or polyacrylates form the matrix; adhesives include polyisobutylene-based polymers; permeation enhancers like ethanol or isopropyl myristate are also used.

3. How do excipients influence nitroglycerin shelf life?
Antioxidants and moisture barriers prevent degradation, extending product shelf life and reducing recalls.

4. Are there innovative excipients on the horizon for nitroglycerin?
Cyclodextrin complexes and nanocarriers are under development to enhance stability and control release.

5. Which market segments show the most promise for new nitroglycerin formulations?
Fast-dissolving sublingual tablets and transdermal patches targeting chronic angina are the primary growth areas.

Citations

[1] MarketsandMarkets. (2022). Angina Market Forecast to 2028.
[2] Ghanem, A., et al. (2021). Modern excipients for transdermal drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 159, 51-62.